West Africa: Ebola Vaccine - Reason to Be Hopeful?

[IRIN] Dakar -News that an Ebola vaccine trialled in Guinea has proved 100 percent effective has elicited both excitement and caution from a range of actors closely involved in the outbreak, which also struck Liberia and Sierra Leone and has claimed more than 11,000 lives since March 2014.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Ebola virus (EBOV) is a non-segmented negative-sense RNA virus that causes a severe human disease. The ongoing EBOV outbreak in the Eastern part of Democratic Republic of the Congo has resulted to date in over 2500 confirmed cases including over 1500 deaths. Difficulties with vaccine administration indicate the necessity for development of new general drugs and therapeutic strategies against EBOV. Host Ser/Thr protein phosphatases, particularly PP1 and PP2A, facilitate EBOV transcription by dephosphorylating the EBOV VP30 protein and switching activity of the polymerase complex toward replication. Previously, we developed ...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
by Gertrud U. Rey The Democratic Republic of the Congo (DRC) is currently experiencing its worst outbreak of Ebola virus disease in history. More than 3,000 people have been infected with the virus, and nearly 1,900 have died since the outbreak began in 2018. The causative virus is “Ebola virus”, the strain previously known as […]
Source: virology blog - Category: Virology Authors: Tags: Basic virology Information antiviral antibodies ebola virus mAb-114 monoclonal antibody neutralizing antibodies non-neutralizing antibodies passive vaccine REGN-EB3 viruses Source Type: blogs
We describe reference materials that have been or are being developed for haemorrhagic fever viruses and consider the issues surrounding their production, particularly that of biosafety where the viruses require specialised containment facilities. Finally, we advocate the use of reference materials at early stages, including research and development, as this helps produce reliable assays and can smooth the path to regulatory approval.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck&Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck&Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Health workers inside a "CUBE" talk to an Ebola patient, while a nurse consults a chart outside. ALIMA Ebola Treatment Centre, Beni, Democratic Republic of the Congo. Two drugs have been found to successfully treat the Ebola virus. Aid agencies have welcomed the news saying it allows communities to access early treatment. Courtesy: World Health Organisation (WHO)By Issa Sikiti da SilvaCOTONOU, Benin, Aug 20 2019 (IPS) While people in the Democratic Republic of Congo (DRC) are slowly being made aware that scientists have discovered two drugs that are effective in treating Ebola, letting go of the fear and anxiety ...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Africa Development & Aid Editors' Choice Featured Health Human Rights Humanitarian Emergencies Population Poverty & SDGs Regional Categories TerraViva United Nations Democratic Republic of Congo (DRC) ebola Source Type: news
A year into an Ebola outbreak in the Democratic Republic of the Congo (DRC), researchers have halted an experimental drug trial there because early results appear so promising. The drugs will be made available to more patients in the DRC, hopefully saving lives as the current outbreak continues. But the decision to end the trial early has implications that go beyond the DRC: it could also change the way infectious disease treatments are studied in years to come. The trial, which began last November and enrolled 681 patients at four sites in the DRC, was meant to test four experimental Ebola therapies: ZMapp (an antibody co...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
[The New Humanitarian] Kampala -Uganda has launched its largest trial of a new experimental Ebola vaccine, as rising cases of the deadly virus in neighbouring Democratic Republic of Congo continue to raise fears of a wider regional outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
[The Conversation Africa] The most recent Ebola outbreak in the Democratic Republic of the Congo (DRC) rages on. There's been a continued increase in the number of new cases for a year since the outbreak was first declared. This is despite the extensive use of an experimental vaccine, new treatments and more rapid response to the outbreak when compared to the West African outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
The most expedient way to test Johnson and Johnson's experimental Ebola vaccine is to administer it during an outbreak, which is the way Merck's vaccine was successfully deployed in Guinea in 2015. Locally, however, there are fears people in the Congo could be used as guinea pigs.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
More News: African Health | Ebola | Ebola Vaccine | Health | Outbreaks | Vaccines